equecabtagene autoleucel

Trade name: Fucacell

Cell therapyexperimental

Clinical trial activity

8 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2020 (NCT05066646)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • BCMAImmunity, passive

    BCMA immunity, passive

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07055724Phase 2Jul 31, 2025Fudan University, IASO Pharma Inc.
NCT06902844N/AApr 5, 2025Huazhong University of Science and Technology, IASO Pharma Inc.
NCT06464991Phase 3Mar 27, 2024Chinese Academy of Medical Sciences, IASO Pharma Inc., Zhejiang University
NCT05698303Phase 1May 8, 2023IASO Pharma Inc.
NCT05181501Phase 1Apr 30, 2022IASO Pharma Inc., Nanjing Medical University, Nanjing University
NCT05201118Phase 1Jan 1, 2022Huazhong University of Science and Technology, IASO Pharma Inc.
NCT04561557Early Phase 1 (Phase 1)Sep 22, 2020Huazhong University of Science and Technology, IASO Pharma Inc.
NCT05066646Phase 1/Phase 2 (Phase 2)Apr 1, 2020Chinese Academy of Medical Sciences, IASO Pharma Inc., Tongji University
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
IASO Pharma Inc.For profit8542020
Huazhong University of Science and TechnologyAcademic/Hospital3322020
Chinese Academy of Medical SciencesAcademic/Hospital2022020
Fudan UniversityAcademic/Hospital1012025
Nanjing Medical UniversityAcademic/Hospital1012022
Nanjing UniversityAcademic/Hospital1012022
Tongji UniversityAcademic/Hospital1012020
Zhejiang UniversityAcademic/Hospital1012024
8 organizations
Page 1 / 1